Liquidia, Pharmosa Expand Pact to Develop Sustained Release Inhaled Treprostinil

 

• Liquidia amends exclusive license to include key markets in Europe, Japan and elsewhere
• Liquidia also obtains rights to Pharmosa’s next-generation nebulizers for use with L606
• Pharmosa to receive $3.5 million upfront and up to $157.75 million in additional development and sales milestones tied to commercial sales outside of North America

https://www.globenewswire.com/news-release/2024/10/02/2956774/0/en/Liquidia-and-Pharmosa-Biopharm-Expand-Collaboration-to-Develop-Sustained-Release-Inhaled-Treprostinil-L606.html